The therapeutic goods administration is investigating a spike in adverse event reports related to Vyvanse. However, it has also been reported that there are no issues of concern with the medication. Additionally, there are apparent shortages of ADHD medication, although it is unclear if this is directly related to the investigation into Vyvanse.